OMEGA HEALTHCARE INVESTORS REIT IN (OHI)
Sector: Real Estate
2026 Annual Meeting Analysis
OMEGA HEALTHCARE INVESTORS REIT IN · Meeting: June 5, 2026
Directors FOR
8
Directors AGAINST
0
Say on Pay
FOR
Auditor
AGAINST
Director Elections
Election of eight members to Omega's Board of Directors
Director since 2018 (over 24 months tenure); OHI's 3-year total return of 107% outperforms the peer group median by +73.9pp, well above the 65pp trigger threshold for strong positive TSR, so no TSR concern applies; no overboarding (1 outside public board), no attendance issues, and brings strong accounting/REIT expertise as a CPA and former KPMG partner.
Director since 2013; OHI's strong 3-year outperformance versus peers (+73.9pp) does not trigger the TSR concern; no overboarding issues (no current public board seats listed as active), no attendance issues flagged, and brings relevant healthcare investment banking and financial expertise.
Director since 2021 (over 24 months tenure); OHI's strong 3-year outperformance versus peers does not trigger any TSR concern; holds 2 outside public board seats (Avanos Medical, Phreesia), which is within the 4-board overboarding limit, and brings relevant healthcare and pharmaceutical expertise.
Director since 2013; OHI's strong 3-year TSR outperformance versus peers (+73.9pp) does not trigger the TSR concern; holds 1 active outside public board seat (Integra LifeSciences), well within limits, and brings deep healthcare operating experience.
Director since 2020 (over 24 months tenure); OHI's strong 3-year outperformance versus peers does not trigger any TSR concern; Mr. Jacobs is a sitting CFO at Hilton but holds no other outside public board seats, so the sitting-CEO overboarding rule does not apply; brings strong real estate, financial reporting, and capital markets expertise.
CEO and director since 2002; OHI's 3-year total return of 107% outperforms the disclosed peer group median by +73.9pp, well above the 65pp trigger threshold, so no TSR underperformance concern applies; holds 1 outside public board seat (COPT Defense Properties), within the 2-seat limit for sitting CEOs; attendance confirmed above 75%.
Director since 2000; OHI's strong 3-year outperformance versus peers does not trigger the TSR concern; holds 1 active outside public board seat (Cushman & Wakefield, appointed October 2025), within limits, and brings extensive commercial real estate and mortgage REIT expertise.
Director since 2018; OHI's strong 3-year outperformance versus peers (+73.9pp) does not trigger the TSR concern; holds 1 outside public board seat (Amicus Therapeutics), within limits, and brings healthcare executive and financial leadership experience.
All eight director nominees receive a FOR vote. OHI's 3-year total shareholder return of 107% outperforms its disclosed compensation peer group median by +73.9 percentage points, which does not trigger the underperformance threshold of 65pp applicable to companies with strong positive absolute returns. No directors are overboarded, all attended more than 75% of meetings, no independence or familial relationship concerns were identified, and the board discloses a comprehensive skills matrix demonstrating relevant expertise across healthcare, real estate, finance, and governance.
Say on Pay
✓ FORCEO
C. Taylor Pickett
Total Comp
$14,020,475
Prior Support
95.9%%
CEO total compensation of approximately $14.0 million is within a reasonable range for a healthcare REIT CEO at Omega's ~$14 billion market cap, and prior shareholder support has been 93% or higher for each of the past ten years, confirming broad shareholder acceptance of the pay program. The pay structure is well-designed: approximately 88% of the CEO's target compensation is variable and at-risk, with 60% of the long-term equity portion tied to rigorous three-year absolute and relative total shareholder return performance hurdles — and those hurdles were meaningfully met in the period ended December 31, 2025, with absolute TSR of 23.4% exceeding the high-performance level and relative TSR slightly exceeding the target level versus the FTSE Nareit Equity Health Care Index. The company has a meaningful clawback policy adopted in compliance with SEC and NYSE requirements, no guaranteed bonuses, and OHI's stock performance over 3 years (107% total return) strongly outperforms both its peer group and the ^FNER benchmark, confirming that above-target incentive pay was genuinely earned.
Auditor Ratification
✗ AGAINSTAuditor
Ernst & Young LLP
Tenure
33 yrs
Audit Fees
$2,181,300
Non-Audit Fees
$1,352,400
EY has served as Omega's auditor since 1992 — a tenure of approximately 33 years, which exceeds our 25-year threshold that triggers a No vote. While the non-audit fee ratio is 62% (tax fees of $1,352,400 divided by audit fees of $2,181,300), which on its own would also raise an independence concern, the primary trigger here is the exceptionally long tenure. The proxy does not provide a specific and compelling rationale for continued engagement — it notes EY's qualifications and industry knowledge but does not disclose a concrete multi-year rotation plan or other mitigating commitment that would justify waiving the tenure concern.
Overall Assessment
Omega Healthcare Investors' 2026 annual meeting presents three standard proposals: director elections (all eight nominees receive a FOR vote given the company's outstanding 3-year total shareholder return of 107%), Say on Pay (FOR, given a well-structured pay-for-performance program with strong shareholder support and demonstrated TSR alignment), and auditor ratification (AGAINST Ernst & Young due to a 33-year tenure that significantly exceeds our 25-year independence threshold and a non-audit fee ratio of 62% that also raises independence concerns). Shareholders who agree with the board on directors and executive compensation but share concerns about auditor independence after more than three decades with the same firm should vote FOR on Proposals 1 and 3 and AGAINST on Proposal 2.
Compensation Peer Group
13 companies disclosed in 2026 proxy filing